Vol. 28, No. 6, 2008
Issue release date: October 2008
Am J Nephrol 2008;28:958–973
In-Depth Topic Review
Add to my selection

Dyslipidemia in Chronic Kidney Disease: An Approach to Pathogenesis and Treatment

Tsimihodimos V. · Dounousi E. · Siamopoulos K.C.
Department of Nephrology, Medical School, University of Ioannina, Ioannina, Greece
email Corresponding Author


 goto top of outline Key Words

  • Lipids
  • Chronic kidney disease
  • Erythropoietin
  • Hypolipidemic drugs

 goto top of outline Abstract

Background/Aims: Cardiovascular disease (CVD) is a major cause of mortality in patients with mild to moderate chronic kidney disease (CKD) and end-stage renal disease (ESRD). Dyslipidemia has been established as a well-known traditional risk factor for CVD in the general population and it is well known that patients with CKD exhibit significant alterations in lipoprotein metabolism. In this review the pathogenesis and treatment of renal dyslipidemia are discussed. Methods:Studies on lipid abnormalities in CKD stages 1–4, in nephrotic syndrome, and in hemodialysis and peritoneal dialysis patients are analyzed, as well as the lipid profile of kidney graft recipients. Also, the results of the effects of epoietin treatment and hypolipidemic drugs in CKD patients are reported. Results: Disturbances in lipoprotein metabolism are evident even at the early stages of CKD and usually follow a downhill course that parallels the decline of renal function. However, several intrinsic or exogenous factors can influence the phenotypic expression of these alterations. According to the literature, current evidence suggests that unlike dialysis patients, mild to moderate CKD patients could be benefit from the use of statins. Conclusion: The use of statins is indicated in patients with mild to moderate CKD, while in subjects with ESRD lipid-lowering therapy should be individualized.

Copyright © 2008 S. Karger AG, Basel

goto top of outline Background

The incidence and prevalence of chronic kidney disease (CKD) are increasing worldwide and are associated with poor outcomes. According to the 1999–2004 National Health and Nutrition Examination Survey (NHANES), the prevalence of CKD among the USA population is 15.3% [1]. Although there is still some controversy whether CKD represents an independent causal risk factor for incident cardiovascular disease (CVD), accumulating evidence over the last decade marks out CVD as the major cause of mortality in patients with mild to moderate CKD and end-stage renal disease (ESRD) [2, 3]. It becomes apparent that the severity of CKD along with CVD severity in any population makes a ‘devastated’ combination for both patients and healthcare systems. Approximately 50% of patients with ESRD die from a cardiovascular event [4], which indicates a cardiovascular mortality that is 30 times higher in dialysis patients and 500 times higher in 25- to 34-year-old ESRD patients than in individuals from the general population of the same age and race [2, 4]. Premature CVD extends from mild to moderate stages of CKD. A pooled analysis of four community-based studies showed that moderate renal insufficiency carries a 19% excess risk of cardiovascular complications [5]. In a retrospective cohort study only a tiny minority of patients (0.5–1%) with mild to moderate CKD developed ESRD over a 5-year follow-up, while as many as 19 and 24% of these patients with mild and moderate renal insufficiency, respectively, died mostly of cardiovascular complications in the same period [6].

In the general population as much as 75% of the excess risk of coronary heart disease could be explained by traditional Framingham risk factors [7]. However, use of traditional risk factors underestimates the CVD risk in patients with CKD [8], while the Framingham predictive instrument demonstrates poor overall accuracy in predicting cardiac events in patients with mild to moderate CKD [9]. Moreover, traditional CVD risk factors were found often to relate to outcome in ESRD dialysis patients in an opposite direction, a phenomenon termed ‘reverse epidemiology’ [10]. The introduction of uremia-related, non-traditional CVD risk factors and evaluation of their corresponding biomarkers were thought to enhance the clinical ability to predict cardiovascular events in patients with all stages of CKD. However, studies investigating the usefulness of current CVD biomarkers have concluded that they only add moderately to traditional risk factors for risk assessment of individuals both with almost normal renal function [11] as well as with mild to moderate CKD [12, 13].

Dyslipidemia has been established as a well-known traditional risk factor for CVD in the general population and large-scale observational studies have shown that total and low-density lipoprotein (LDL)-cholesterol values are two of the most important independent predictors of cardiovascular morbidity and mortality [14]. Also, it is well known that patients with impaired renal function exhibit significant alterations in lipoprotein metabolism, which in their most advanced form may result in the development of severe dyslipidemia. In this review studies on the pathogenesis of renal dyslipidemia and the results of drug therapy are discussed.


goto top of outline Lipids in CKD Stages 1–4

The process of exogenous and endogenous pathways of lipid metabolism is a complicated phenomenon in both normal and abnormal conditions. A schematic presentation of both pathways is shown in figure 1.

Fig. 1. Schematic presentation of the exogenous (a) and endogenous (b) pathway of lipoprotein metabolism. LpL = Lipoprotein lipase; FFA = free fatty acids; LRP = LDL-receptor-related protein; CE = cholesterol ester; TRG = triglycerides; CETP = cholesteryl ester transfer protein; apo = apolipoprotein; VLDL = very-low-density lipoprotein; IDL = intermediate-density lipoprotein; LDL = low-density lipoprotein; HDL = high-density lipoprotein; LDL-R = LDL receptor; HL = hepatic lipase.

Although lipid abnormalities were originally considered as complications of ESRD, these changes can be present in early stages of CKD and may actively participate in the pathogenesis of serious complications such as atherosclerotic vascular disease. Although the nature of dyslipidemia can be significantly influenced by several intrinsic (nephrotic range proteinuria, concomitant diseases such as diabetes mellitus, hereditary disorders of lipid metabolism) or exogenous (epoietin administration, drugs such as steroids, calcineurin inhibitors, etc.) factors, the most common quantitative lipid abnormalities in predialysis CKD patients are hypertriglyceridemia, increased concentrations of triglyceride-rich lipoprotein remnants, reduced high-density lipoprotein (HDL)-cholesterol levels as well as increased concentrations of lipoprotein(a) (Lp(a)) [15]. Notably, total and LDL-cholesterol levels are usually within normal limits or slightly reduced in these individuals (table 1) [16].

Table 1. Effects of renal failure and renal replacement modalities on serum lipids

Hypertriglyceridemia represents an early feature of renal failure. Indeed, previous studies have shown that patients with impaired renal function exhibit increased concentrations of triglycerides even though serum creatinine levels are within normal limits [17, 18]. In addition, individuals with renal insufficiency usually display abnormal increases in serum triglyceride levels after a fat meal (postprandial lipemia) [19]. Experimental studies revealed that the accumulation of triglyceride-rich lipoproteins (very-low-density lipoprotein (VLDL), chylomicrons and their remnants) in individuals with predialysis CKD is mainly due to their decreased catabolism [20]. The downregulation of the expression of several genes [21,22,23] along with the changes in the composition of lipoprotein particles [24] and the direct inhibitory effect of various uremic ‘toxins’ on the enzymes involved in lipid metabolism [25], represent the most important pathophysiological mechanisms underlying the development of hypertriglyceridemia in renal failure. Interestingly, it has been proposed that secondary hyperparathyroidism may also contribute to the impaired catabolism of triglyceride-rich lipoproteins [26, 27] and that parathyroidectomy or the administration of the calcium channel blocker verapamil [28] may partially ameliorate the hypertriglyceridemia of CKD. It is well known that impaired insulin sensitivity represents an early feature of CKD [17,18,19]. Thus, it could be hypothesized that the insulin resistance-driven overproduction of VLDL may significantly contribute to the development of hypertriglyceridemia in CKD patients. However, the role of the increased hepatic production of triglyceride-rich lipoproteins in the pathogenesis of renal dyslipidemia remains a subject of debate [20].

Epidemiological studies have shown that HDL-cholesterol levels are inversely related to the future cardiovascular risk [29]. HDL particles possess multiple antiatherogenic activities including reverse cholesterol transport (transport of surplus cholesterol from the arterial wall to the liver for excretion) as well as antioxidative, anti-inflammatory and antithrombotic functions, which are attributed to HDL-associated apolipoproteins (mainly apolipoprotein AI) and enzymes (paraoxonase-1, platelet-activating factor acetylhydrolase and lecithin-cholesterol acyltransferase (LCAT)) [30]. A schematic presentation of the normal reverse cholesterol transport pathway is shown in figure 2. Studies in patients or laboratory animals with predialysis renal failure consistently reveal decreased concentrations of HDL-cholesterol compared to individuals with normal renal function [31, 32]. Several mechanisms, working in concert, may underlie this reduction in HDL-cholesterol levels, which is usually indicative of impaired reverse cholesterol transport. Thus, uremic patients usually exhibit decreased levels of apolipoproteins AI and AII (the main protein constituents of HDL) [32], diminished activity of LCAT (the enzyme responsible for the esterification of free cholesterol in HDL particles) [22, 33] as well as increased activity of cholesteryl ester transfer protein [34] that facilitates the transfer of cholesterol esters from HDL to triglyceride-rich lipoproteins thus reducing the serum concentrations of HDL-cholesterol. In addition to their reduced efficiency as cholesterol acceptors, HDL particles from individuals with renal failure may also possess impaired antioxidative and anti-inflammatory function. This impairment can, at least in part, be attributed to the reduction in the activities of HDL-associated enzymes [35, 36].

Fig. 2. Schematic presentation of the reverse cholesterol transport pathway. VLDL = Very-low-density lipoprotein; HDL = high- density lipoprotein; FC = free cholesterol; CE = cholesterol ester; TRG = triglycerides; CETP = cholesteryl ester transfer protein; ABC 1 = ATP-binding cassette transporter 1; SR-B1 = scavenger receptor-B1; LCAT = lecithin-cholesterol acyltransferase.

Lp(a) represents an LDL-like particle distinguished from LDL by the presence of apolipoprotein(a) (apo(a)), which is attached to the apolipoprotein B-100 molecule through disulfide linkage [37]. Apo(a) is highly homologous to the plasma protease zymogen plasminogen and thus it has been suggested that Lp(a) may promote thrombogenesis by inhibiting fibrinolysis [37]. Studies in healthy individuals and in patients with CKD have shown that serum Lp(a) levels are strongly and negatively associated with apo(a) isoform size. Indeed, subjects who have lowmolecular-weight apo(a) isoforms show on average higher Lp(a) concentrations compared to those who have high-molecular-weight isoforms [38]. The large concentration gradient of Lp(a) between the aorta and renal vein [39] as well as the identification of apo(a) fragments in urine [40] suggest that the kidney may actively participate in the degradation of Lp(a). Thus, it is not surprising that patients with primary kidney diseases (even those with normal GFR values) usually exhibit markedly elevated concentrations of Lp(a) [41, 42] as well as increased concentrations of LDL-unbound apo(a) [43]. However, recently published studies indicate that the negative association between renal function and Lp(a) levels is phenotype-specific. Thus, predialysis renal failure patients with high-molecular-weight apo(a) isoforms tend to have much higher Lp(a) values than apo(a) phenotype-matched healthy controls, whereas patients with kidney diseases who exhibit low-molecular-weight apo(a) isoforms have similar Lp(a) concentrations with phenotype-matched healthy individuals, who already have high Lp(a) levels [37, 44]. It is worth mentioning that prospective studies identified small apo(a) isoform size and not Lp(a) level as an independent predictor of total and cardiovascular mortality in CKD patients [45, 46].

In addition to the aforementioned quantitative changes in serum lipoprotein concentrations, patients with CKD display important qualitative alterations in lipid metabolism that cannot be easily assessed with conventional laboratory techniques [16]. Thus, it has been shown that VLDLs from individuals with impaired renal function have increased cholesterol content, while their triglyceride content is usually reduced. In contrast, chronic renal failure usually results in decreased cholesterol content of LDLs and HDLs, whereas the triglyceride content of these particles is relatively increased. Finally, although uremic patients usually have a normal or slightly reduced LDL-cholesterol concentration, they exhibit important disturbances in the density distribution of LDL subfractions that is characterized by a predominance of small, dense LDL particles [47, 48]. These particles are more atherogenic than the large, buoyant ones and can substantially contribute to the pathogenesis of atherosclerotic vascular disease [49].


goto top of outline Lipids in Nephrotic Syndrome

Disturbed lipoprotein metabolism is a consistent feature of the nephrotic syndrome (NS) [50, 51]. The development of this form of secondary dyslipidemia appears to be independent of the underlying renal disease and may substantially contribute to the increased cardiovascular risk that has been observed in these individuals [52] as well as to the progression of renal failure [53]. The most common lipid abnormalities in patients with NS are elevated concentrations of total and LDL-cholesterol as well as a predominance of cholesterol-depleted small, dense LDL particles (table 1) [51, 54]. However, in a considerable number of cases, elevated concentrations of triglycerides (due to accumulation of VLDL and remnant lipoproteins such as intermediate-density lipoprotein (IDL)) can also be observed [51]. In addition, individuals with nephrotic-range proteinuria exhibit increased concentrations of Lp(a) that, in contrast to what is usually noticed in CKD patients without proteinuria, is not phenotype-specific [55]. This means that most patients with the NS have Lp(a) concentrations that are substantially elevated compared with controls of the same apo(a) isoform [55]. Finally, HDL-cholesterol levels have variously been reported to be increased, decreased, or normal in subjects with nephrosis [50, 56].

The pathophysiological mechanisms that are responsible for the development of nephrotic dyslipidemia remain ill defined. In addition, the reasons for the occurrence of two different patterns of dyslipidemia (namely hypercholesterolemia and combined dyslipidemia) have not been fully explained. Nevertheless, it has been proposed that two of the most important determinants of triglyceride levels in patients with NS could be the degree of proteinuria and the deterioration in renal function [31, 57].

Early studies that tried to elucidate the mechanisms behind nephrotic dyslipidemia concluded that increased hepatic production and secretion of apolipoprotein B-containing lipoproteins (VLDL and LDL) is the major cause of the lipid abnormalities observed in this patient population [58,59,60]. According to this hypothesis, the reduced serum albumin levels and/or the decreased plasma oncotic pressure may lead to a coordinated increase in the synthesis of albumin and other proteins by the liver, including lipoproteins [58, 61, 62]. In this context, experimental studies showed that albumin, dextran and other oncotically active macromolecules are equally effective in correcting this abnormality [61, 63, 64]. In contrast to this assumption, the vast majority of the subsequent kinetic studies revealed that the dyslipidemia of NS is primarily a result of defective lipoprotein catabolism, whereas the increased hepatic lipoprotein production is not associated with albumin metabolism and possibly plays a secondary role [57,65,66,67]. In line with this theory are the findings of several research groups who showed impaired intravascular lipolysis of triglyceride-rich lipoproteins and reduced fractional catabolic rates of LDL in individuals with NS. It is well known that the progressive delipidation of triglyceride-rich lipoproteins is facilitated by the action of two different enzymes namely endothelial-bound lipoprotein lipase and hepatic lipase. The expression of the genes of these enzymes has been found to be downregulated in patients with NS [68]. In addition, other factors such as hypoalbuminemia and proteinuria may further decrease the efficiency of lipoprotein lipase-induced lipolysis of triglyceride-rich lipoproteins by interfering with the endothelial binding of the enzyme and by changing the composition of VLDLs in a way that reduces their suitability as lipoprotein lipase substrates, respectively [69].

Recently published studies indicate that individuals with NS exhibit an acquired LDL-receptor deficiency [70]. Although the nature of this deficiency has not been fully characterized, studies in experimental animals have shown that the inefficient translation and/or the increased LDL-receptor protein turnover may represent the most important causes for its development [71, 72]. In addition to these mechanisms, conformational changes in the apolipoprotein B moiety of LDLs may further reduce the affinity of LDL particles for LDL receptor thus contributing to the elevated LDL-cholesterol levels that represent the prominent feature of nephrotic dyslipidemia [54]. The reduced receptor-mediated catabolism of LDL particles along with the upregulation of acyl-coenzyme A:cholesterol acyltransferase (ACAT) gene (the enzyme responsible for cholesterol esterification in hepatocytes) that has been observed in individuals with NS [73] may reduce the free cholesterol content of hepatocytes and thus may lead to the dysregulation of the key enzymes that are involved in cholesterol homeostasis. Indeed, studies in animals with experimental nephrosis revealed an upregulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (the rate-limiting enzyme in cholesterol biosynthesis) [74] as well as a relative reduction in cholesterol 7α-hydroxylase (an enzyme that plays an important role in cholesterol catabolism through the formation of bile acids) [75]. All the aforementioned mechanisms in concert may result in the increased concentration of LDL-cholesterol in individuals with NS. In addition to the elevated LDL-cholesterol levels, patients with heavy proteinuria usually exhibit increased concentrations of Lp(a) independent of the genetically determined apo(a) isoform. Kinetic studies revealed that this increase is mainly due to the increased hepatic production of this lipoprotein whereas the rate of Lp(a) catabolism was not significantly affected by the presence of the NS [76].

Finally, although HDL-cholesterol levels are usually well preserved in individuals with NS, the reverse cholesterol transport (i.e. the transport of excessive cholesterol from the peripheral tissues to the liver for excretion) is usually impaired. This impairment is mainly related to the acquired defect in LCAT activity [77], to the increased cholesteryl ester transfer protein activity [78] as well as to the downregulation of scavenger receptor B-1 (hepatic HDL receptor) that has been observed in patients with NS [79]. In addition to its deleterious effects on the reverse cholesterol transport, the dysregulation of these key enzymes and receptors can also significantly affect the efficiency of the catabolism of triglyceride-rich lipoproteins. Indeed, it is well known that the HDLs, during their maturation from cholesterol-depleted HDL3 to cholesterol-enriched HDL2 particles, donate sufficient amounts of apolipoproteins E and C-II to VLDL and chylomicrons. These apolipoproteins play significant roles in the catabolism of triglyceride-rich lipoproteins since they facilitate their interaction with endothelial-bound lipoprotein lipase and hepatic receptors. As a consequence, the disturbed maturation of HDL particles in individuals with NS further impairs the intravascular delipidation and hepatic removal of VLDLs thus contributing to the development of hypertriglyceridemia [70].

It is noteworthy that the treatment of nephrotic dyslipidemia with the application of LDL-apheresis [80, 81] or with the use of medications such as statins [82] and direct ACAT inhibitors [83] has a favorable effect on some NS-related parameters such as hypoalbuminemia and albuminuria. These observations clearly demonstrate the existence of a vicious circle involving proteinuria and dyslipidemia.


goto top of outline Lipids in Hemodialysis and Peritoneal Dialysis

Dialysis is very effective for the amelioration of uremic symptoms and certain features of uremic toxicity. The initiation of renal replacement therapy as well as the choice of dialysis modality may also influence the phenotypic characteristics of uremic dyslipidemia in patients with ESRD (table 1). However, the lipid and apolipoprotein profile that characterizes predialytic renal failure remains essentially unchanged during long-term hemodialysis (HD) [31, 84]. Thus, HD patients usually display increased concentrations of intact or partially metabolized triglyceride-rich lipoproteins, reduced serum levels of HDL-cholesterol and elevated concentrations of Lp(a). Total and LDL-cholesterol values are within normal limits or reduced in this patient population, whereas the subfractionation of apolipoprotein B-containing lipoproteins usually reveals a predominance of small, dense LDL particles [48]. The pathophysiological mechanisms that underlie the alterations in lipoprotein metabolism in HD patients are generally similar with those described in predialysis renal failure individuals. However, the dialysis procedure may result in additional defects in lipid homeostasis (such as increased catabolic rate of apolipoprotein AI) [85] that reinforce the clinical expression of these mechanisms.

Despite the neutral effect of dialysis on serum lipid profile, certain dialysis-related parameters may significantly affect lipoprotein metabolism and modify the features of dyslipidemia in HD patients. Thus, it has been shown that the use of high-flux polysulfone or cellulose triacetate membranes instead of low-flux membranes is accompanied by a significant reduction in serum triglyceride levels as well as by an increase in apolipoprotein AI and HDL-cholesterol levels [86, 87]. This improvement could, at least in part, be attributed to an increase in the apolipoprotein C-II/C-III ratio which increases the activity of lipoprotein lipase and facilitates the intravascular lipolysis of triglyceride rich-lipoproteins [88]. In addition, the type of dialysate may also significantly affect the serum levels of lipoproteins in HD patients. Indeed, it has been shown that the use of bicarbonate dialysate may result in higher HDL-cholesterol concentrations than the use of acetate dialysate [89]. Another factor that can potentially affect lipoprotein metabolism in HD patients is the repeated use of heparin as an anticoagulant. Heparin releases lipoprotein lipase from the endothelial surface and thus its chronic use may result in lipoprotein lipase depletion and defective catabolism of triglyceride-rich lipoproteins. However, the studies that tested the role of heparin in the pathogenesis of HD-induced dyslipidemia revealed contradictory results [90,91,92]. In addition, controversy exists as to whether low-molecular weight heparins have a more favorable effect on the lipid profile of HD patients compared to standard unfractionated heparin [93, 94]. Finally, recent studies indicate that the use of the phosphate-binder sevelamer hydrochloride significantly reduces the concentrations of total cholesterol and apolipoprotein B in HD patients [95]. Obviously, the cholesterol-lowering properties of this compound are irrelevant to phosphate reduction and can be mainly attributed to its bile acid sequestrating properties.

In contrast to HD patients whose serum lipoprotein concentrations resemble those of predialysis renal failure subjects, continuous ambulatory peritoneal dialysis (CAPD) patients usually exhibit a more atherogenic lipid profile that is characterized by higher total and LDL-cholesterol values, increased apolipoprotein B concentrations, and more pronounced hypertriglyceridemia [84, 96]. In addition, CAPD patients have increased concentrations of small, dense LDL, higher Lp(a) values and reduced HDL-cholesterol concentrations compared to healthy age- and sex-matched individuals [48, 96]. The pathophysiological mechanisms that exacerbate dyslipidemia in CAPD individuals are not well characterized. However, a number of factors have been proposed to play contributory roles in this exacerbation. It is well known that CAPD patients lose substantial amount of proteins into the peritoneal dialysate, resembling the protein losses observed in NS. This protein loss may, in turn, stimulate the hepatic production of albumin and cholesterol-enriched lipoproteins thus leading to elevated concentrations of LDL-cholesterol and Lp(a) [97,98,99,100,101]. In addition, the absorption of glucose from the dialysis fluid and the resultant increase in insulin levels may enhance the hepatic synthesis and secretion of VLDL and possibly that of other lipoproteins such as Lp(a) [102]. Although no direct correlation has been observed between peritoneal glucose absorption and serum lipid levels in peritoneal dialysis patients, recent studies indicate that the reduction in glucose load with the use of less absorbed icodextrin-containing dialysis solution instead of glucose for the overnight dwell sufficiently reduces the serum levels of total and LDL-cholesterol as well as the concentrations of triglycerides and small, dense LDL particles [103, 104]. It should be noted that even though substantial amounts of apolipoproteins and intact lipoproteins (especially HDL) are lost via the peritoneal cavity in CAPD patients, the pathophysiological significance of these losses as well as their impact on lipoprotein metabolism remain indeterminate [105, 106].

In a recent study we investigated the efficiency of the phosphate-binder sevelamer hydrochloride in the treatment of hyperphosphatemia and its influence on serum lipid parameters in patients on CAPD. The data from this prospective, randomized, cross-over study indicate that, over a period of 8 weeks, the drug effectively lowered serum phosphorus and also had a significant beneficial effect on both total and LDL-cholesterol serum levels [107].


goto top of outline Lipids in Kidney Graft Recipients

The numberof kidney transplant recipients has increased considerably during the latter years [1]. As a consequence, knowledge of the impact of renal transplantation on various metabolic pathways is of paramount importance. Theoretically it could be expected that the restoration of normal (or near-normal) renal function after a successful renal transplantation might favorably affect the metabolism of lipoproteins in a way opposite to that observed during the development of uremia. However, the various metabolic changes that take place after renal transplantation cannot be evaluated outside the context of immunosuppressive therapy. In addition, since immunosuppressive regimens usually include more than one medication, the individual contribution of either drug to the observed metabolic disturbances cannot be easily interpreted.

Although the results of the trials that evaluated the lipid profile in renal graft recipients are contradictory, numerous studies revealed deterioration in the metabolism of apolipoprotein B-containing lipoproteins after successful renal transplantation [108,109,110,111]. This is characterized by elevated values of total, VLDL and LDL-cholesterol as well as increased concentrations of triglycerides and apolipoprotein B (table 1) [108,109,110,111]. In addition, determination of the LDL subfraction profile in these subjects usually discloses a preponderance of small, dense LDL particles [112, 113]. HDL-cholesterol levels tend to increase in the post-transplant period and this change has been mainly attributed to the effects of corticosteroids [114]. Finally, Kerschdorfer et al. [115] clearly demonstrated a significant decrease in the concentrations of Lp(a) after renal transplantation (table 1). The magnitude of this reduction was significantly influenced by the mode of dialysis before transplantation (greater reductions were observed in CAPD patients), the apo(a) isoform size (patients with high-molecular-weight isoforms exhibited greater reductions) and the type of immunosuppressive therapy (azathioprine was the only drug that had a positive dose-related effect on the relative decreases of Lp(a) concentrations) [115]. Finally, the deterioration of renal function after transplantation (as indicated by a decreasing GFR or increasing proteinuria) significantly limited or even reversed the observed decreases in Lp(a) values [115]. There is little doubt that among the immunosuppressive drugs usually used in kidney graft recipients cyclosporine has the most detrimental effects on lipoprotein metabolism. It has been shown that cyclosporine administration significantly increases the concentrations of LDL-cholesterol and triglycerides while it reduces the serum values of HDL-cholesterol [116,117,118]. On the other hand tacrolimus, azathioprine and mycophenolate mofetil usually induce only minor changes in serum lipid levels. In this context, previous studies have shown that the conversion of cyclosporine to one of these drugs is followed by a significant decrease in the levels of total and LDL-cholesterol [118,119,120]. In addition, the substitution of cyclosporine for tacrolimus also reduces the concentrations of triglycerides [120] while the conversion of cyclosporine to mycophenolate mofetil is followed by a further reduction in HDL-cholesterol levels [118].

It has been proposed that in addition to its potential involvement in the pathogenesis of cardiovascular disease in kidney graft recipients, dyslipidemia may also contribute to the chronic allograft dysfunction that is commonly observed in this patient population [121]. These assumptions, along with the differential impact of the various immunosuppressive medications on lipoprotein metabolism, underlie the need for individually adjusted immunosuppressive therapy and possibly necessitate the use of hypolipidemic drugs in dyslipidemic kidney graft recipients.


goto top of outline Lipids in CKD Patients Receiving Epoietin Treatment

Recombinant human erythropoietin (rhEPO) represents the cornerstone of the treatment of renal anemia in patients with ESRD. However, a considerable number of studies revealed that rhEPO not only affects erythropoiesis but also may have important metabolic actions in maintenance dialysis patients [122,123,124]. Early studies attempting to investigate the effect of rhEPO administration on lipoprotein metabolism revealed contradictory results [125,126,127]. However, most of these studies had insufficient power to detect small changes in serum lipid values. In their pioneer study Pollock et al. [128] showed that the administration of rhEPO for 1 year significantly reduces the serum levels of total cholesterol and triglycerides as well as the concentrations of apolipoprotein B in maintenance HD patients. These observations were partially confirmed by a subsequent study showing that the beneficial effect of rhEPO on lipid homeostasis is confined to individuals who do not increase their energy intake during the study period [129]. In contrast, patients who increase their food intake during rhEPO administration display an important deterioration in serum lipid profile that is characterized by significant increases in the concentrations of total and LDL-cholesterol, triglycerides and apolipoprotein B [129]. On the other hand, studies with longer follow-up periods (2 years) failed to detect any significant effect of rhEPO on apolipoprotein B-containing lipoprotein metabolism and concluded that the only effect of long-term rhEPO administration is an increase in the concentrations of apolipoprotein AI [126].

The effects of rhEPO on serum lipid levels in patients with predialysis CKD were recently investigated. In these studies the administration of rhEPO alone or in combination with keto acids and a low-protein diet significantly decreased the concentrations of total and LDL-cholesterol as well as the serum values of triglycerides and apolipoprotein B [130, 131]. In addition, rhEPO also significantly increased the concentrations of HDL-cholesterol and this increase was positively correlated with that in hemoglobin levels [131]. This finding, along with the rhEPO-induced increase in HDL-associated platelet-activating factor acetylhydrolase activity that has been observed by our group [132], clearly demonstrates that the administration of rhEPO in patients with predialysis CKD improves the antiatherogenic function of HDLs in a number of different ways.

The mechanisms that underlie the rhEPO-induced changes in lipid metabolism remain ill defined. However, it is well known that rhEPO increases the exercise capacity [133], improves the insulin sensitivity [122, 134] and increases the activities of both lipoprotein and hepatic lipase [135] in individuals with ESRD. These actions, along with the increased tissue oxygenation resulting from the correction of anemia may favorably affect lipoprotein metabolism. Finally, the antioxidative and anti-inflammatory properties of erythropoietin as well as the preservation of renal function that follows its administration in individuals with CKD may also play contributory roles [131, 136].


goto top of outline Drug Therapy of Dyslipidemia in CKD Patients

Interventional studies have shown that the pharmacological reduction of total and LDL-cholesterol values is followed by an impressive decrease in the risk of the development of ischemic events. Thus, based on the extremely high cardiovascular mortality that characterizes the individuals with CKD [2, 3], the Work Group for Kidney Disease Outcomes Quality Initiative (K/DOQI) published the Clinical Practice Guidelines for Managing Dyslipidemias in CKD [137] and proposed the adoption of Adult Treatment Panel (ATP) III LDL-cholesterol targets [138] for individuals with stage 5 CKD. In other words, these guidelines suggested that in individuals with ESRD an LDL-cholesterol value lower that 100 mg/dl should be achieved. However, the utilization of LDL-cholesterol as a target for preventive therapy in patients with CKD has several important limitations. It is well known that LDL-cholesterol is commonly determined by the Friedewald calculation in specimens from fasting subjects and with triglyceride concentrations of <400 mg/dl. However, the equation is considerably inaccurate even at triglyceride concentrations of 200–400 mg/dl [139]. Thus, since uremic dyslipidemia is mainly characterized by increased concentrations of triglycerides, the use of Friedewald equation for the determination of LDL-cholesterol values in this patient population may result in important measurement errors. As a consequence, it has been proposed that a number of different equations that take into consideration the serum levels of apolipoprotein B may be more appropriate in individuals with impaired renal function [140]. An alternative approach to this problem is the calculation of non-HDL-cholesterol (total cholesterol – HDL cholesterol) values. The calculation of this parameter (which represents the sum of the concentrations of all apolipoprotein B-containing particles) overcomes the methodological limitations of LDL-cholesterol determination, does not require fasting specimens [141] and, most importantly, in addition to LDL particles takes into account the concentrations of all apolipoprotein B-containing particles such as VLDL, Lp(a), IDL and chylomicron remnants [142]. Several studies have shown that the concentrations of these particles (that are not captured by conventional LDL measurement) are elevated in patients with renal failure and may independently contribute to the determination of future cardiovascular risk [143, 144]. The National Kidney Foundation guidelines suggest non-HDL-cholesterol values of <130 mg/dl as a secondary target of therapy in individuals with triglyceride values of >200 mg/dl [137]. However, since observational studies have proved the predictive value of the non-HDL-cholesterol concentration in HD patients [145], other investigators suggest its use as a therapeutic target regardless of the serum triglyceride levels [146].

Another set of data that questions the role of cholesterol concentration as a target for preventive or therapeutic interventions in individuals with ESRD comes from studies attempting to determine the impact of plasma lipoprotein concentrations on total and cardiovascular mortality in this patient population. Indeed, although high total and LDL-cholesterol values can predict cardiovascular events in HD patients [147], the large observational studies that tested the impact of hypercholesterolemia on total and cardiovascular mortality revealed contradictory results. Thus, in contrast to what is observed in the general population, the initial studies showed an inverse relationship between cholesterol values and mortality rates in individuals with ESRD (so-called reverse epidemiology) [148, 149]. In contrast, other studies demonstrated that reverse epidemiology is, in fact, the result of the confounding effect of malnutrition and/or inflammation that are commonly observed in the advanced stages of renal failure [150,] [151]. Thus, although in the absence of malnutrition/inflammation high cholesterol values are associated with higher mortality rates, in the presence of these ‘disturbances’ the association of cholesterol with mortality risk can be modified or even reversed [150, 151]. However, it must be mentioned that the aforesaid assumptions were not confirmed by the results of recent studies. Indeed, Kilpatrick et al. [152] in a cohort of 15,859 HD patients showed that the positive relationship between cholesterol values and cardiovascular death risk may be confined to certain racial subgroups such as black HD patients. These discrepancies clearly show that further studies are needed to delineate the impact of lipoprotein concentrations on total and cardiovascular risk in individuals with ESRD.

It is possible that the most important factor that limits the use of hypolipidemic drugs in individuals with CKD is the contradictory results of the studies that tried to delineate the effects of statins on total and cardiovascular mortality in this patient population. It is well known that statins are by far the most commonly prescribed hypolipidemic drugs in the general population, and numerous large, randomized, prospective studies have shown that their use is accompanied by an impressive reduction in the incidence of cardiovascular events [153]. On the other hand, data from studies conducted in individuals with CKD suggest that the effect of these drugs on cardiovascular morbidity and mortality in this patient population is significantly influenced by the severity of renal dysfunction. Thus, in several large, prospective, placebo-controlled trials of statins, post hoc analyses of subgroups with mild to moderate renal failure revealed a significant reduction in cardiovascular morbidity and mortality [154,155,156,157]. The same results were also obtained by studying prespecified subgroups of individuals with impaired renal function in the HPS [158] and ASCOT-LLA [159] studies that utilized simvastatin and atorvastatin, respectively. In addition, the recently published ALERT study revealed that although the administration of fluvastatin in renal transplant recipients did not significantly reduce the risk of the composite primary end point (cardiac death, nonfatal myocardial infarction, or coronary intervention procedure), it resulted in a significant decrease in the risk of cardiac death and nonfatal myocardial infarction [160]. It must be mentioned that the adverse event rates in these statin trials were similar to those observed in the placebo arms. As a consequence, the use of statins as a first-line therapy for the prevention of ischemic events in dyslipidemic individuals with CKD (stages 1–3) seems to be a safe, reasonable and evidence-based approach.

Although several observational studies showed that the administration of statins in individuals with ESRD is associated with a significant decrease in cardiovascular and all-cause mortality [161,162,163], these observations were not confirmed in the subsequent prospective, placebo-controlled trials. In the 4D (Die Deutsche Diabetes Dialyse) trial 1,255 diabetic subjects who had been on maintenance HD for less than 2 years were randomized to receive either placebo or 20 mg/day of atorvastatin [164]. Overall, after a mean follow-up period of 2.4 years, atorvastatin did not significantly reduce the risk of the composite primary end point (cardiovascular death, nonfatal myocardial infarction and stroke), despite a significant 42% reduction in LDL-cholesterol concentration [165]. However, this study had several methodological limitations. Thus, it must be noted that the majority of cardiovascular events in the 4D study were possibly non-ischemic in nature (mainly congestive heart failure and sudden deaths), although the ischemic origin of sudden deaths cannot be definitely excluded. In addition, another confounding factor could be that a significant proportion of individuals in the placebo arm (about 15%) also received a non-study statin. Nevertheless, similar findings were also reported in a recent small Scandinavian study that showed a significant decrease in cardiovascular end points after atorvastatin administration in patients with predialysis renal failure but no effect in individuals who were on maintenance HD [166]. Several mechanisms have been proposed for the explanation of the failure of statins to improve cardiovascular outcomes in individuals with advanced renal failure. Thus, it has been suggested that the development of atherosclerosis in this population may have a different pathophysiological basis (arterial wall calcification, inflammation, etc.), whereas other investigators emphasized that lipoproteins other than LDL (such as Lp(a), IDL, etc.) may play a significant role in the initiation and progression of coronary atherosclerosis [146, 167, 168]. Finally, it has been proposed that the beneficial effect of statins may be confounded by the presence of micro-inflammation and/or malnutrition in individuals with ESRD [169]. Whatever the cause, and while awaiting the results of ongoing statin trials [170, 171] in this patient population, we believe that the decision for the administration of statins in HD patients should be individualized.

It is well known that fibrates reduce the concentrations of triglycerides, increase the serum concentrations of HDL-cholesterol and induce a shift in the LDL subfraction distribution towards larger and more buoyant particles [172]. Thus, these drugs could represent an ideal option for the treatment of uremic dyslipidemia. However, it has been shown that the administration of fibrates (possibly with the exception of gemfibrozil) in individuals with impaired renal function is associated with an extremely high risk of muscular toxicity [173, 174]. In addition, these drugs also significantly increase serum creatinine values. Although it has been proposed that this increase does not represent a true deterioration in renal function but rather is due to increased metabolic production of creatinine, other investigators have reported cases of nonreversible renal failure after fibrate administration [173]. In addition, the impact of fibrates on cardiovascular end points in individuals with impaired renal function has not been extensively studied. Thus, although an observational study suggested that the use of fibrates in patients with renal failure does not reduce total mortality [161], a post hoc analysis of the secondary prevention VA-HIT study revealed that the administration of gemfibrozil in individuals with moderate renal failure reduced the risk of the primary end point (coronary death or nonfatal myocardial infarction) by 27% [175]. In our opinion fibrates should be used only in the subpopulation of patients with CKD who exhibit extremely elevated triglycerides values (>500 mg/dl). In these cases the risk of acute pancreatitis justifies the use of gemfibrozil as the fibrate of choice in individuals with impaired renal function [173], although previous studies have shown that its administration in CKD patients may, in some cases, be followed by muscle aches and a significant rise in serum creatine phosphokinase values [176]. The administration of ω–3 polyunsaturated fatty acids may also play a role in the management of this extremely rare condition [177].

A number of other hypolipidemic drugs that are increasingly used in the general population (such as niacin, ω–3 polyunsaturated fatty acids and ezetimibe) may also play important roles in the management of uremic dyslipidemia. However, although small studies have documented the efficiency and the tolerability of these substances in patients with chronic kidney disease, there is a lack of evidence concerning their impact on the cardiovascular risk in this patient population. Further prospective, placebo-controlled studies are needed to delineate the role of these drugs in the treatment of dyslipidemia in individuals with CKD.


goto top of outline Conclusions

Dyslipidemia represents an integral component of CKD. Disturbances in lipoprotein metabolism (mainly accumulation of intact or partially metabolized apolipoprotein B-containing particles as well as reduced concentrations of HDL-cholesterol) are evident even at the early stages of CKD and usually follow a downhill course that parallels the deterioration in renal function. Since several intrinsic (genetic, primary kidney disease) or exogenous (drugs, method of renal replacement) factors can influence the phenotypic expression of these alterations, the precise knowledge of the pathophysiological mechanisms that underlie their development is of paramount importance. Recently published studies indicate that dyslipidemia in these patients may actively participate in the pathogenesis of CVD as well as in the deterioration of renal function. Thus, we believe that the current evidence dictates the use of statins in patients with mild to moderate CKD. On the other hand, in subjects with ESRD the decision for the institution of lipid-lowering therapy should be individualized. Thus, in individuals with established CVD as well as in those who run a high risk for acute pancreatitis due to severe hypertriglyceridemia, the administration of hypolipidemic drugs (statins and gemfibrozil, respectively) is a safe and reasonable approach. However, it should be kept in mind that further studies are needed to delineate the clinical efficacy of these interventions.

 goto top of outline References
  1. Whaley-Connell AT, Sowers JR, Stevens LA, McFarlane SI, Shlipak MG, Norris KC, Chen SC, Qiu Y, Wang C, Li S, Vassalotti JA, Collins AJ; Kidney Early Evaluation Program Investigators: CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999–2004. Am J Kidney Dis 2008;51(suppl 2):S13–S20.

    External Resources

  2. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154–2169.
  3. Hallan SI, Coresh J, Astor BC, Asberg A, Powe NR, Romundstad S, Hallan HA, Lydersen S, Holmen J: International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol 2006;17:2275–2284.
  4. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32:S112–S119.
  5. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, Salem DN, Levey AS, Sarnak MJ: Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 2004;15:1307–1315.
  6. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296–1305.
  7. Magnus P, Beaglehole R: The real contribution of the major risk factors to the coronary epidemics: time to end the ‘only-50%’ myth. Arch Intern Med 2001;161:2657–2660.
  8. Sarnak MJ, Coronado BE, Greene T, Wang SR, Kusek JW, Beck GJ, Levey AS: Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol 2002;57:327–335.
  9. Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS, Sarnak MJ: The Framingham predictive instrument in chronic kidney disease. J Am Coll Cardiol 2007;50:217–224.
  10. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD: Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003;63:793–808.
  11. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Selhub J, Robins SJ, Benjamin EJ, D’Agostino RB, Vasan RS: Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006;355:2631–2639.
  12. Addabbo F, Mallamaci F, Leonardis D, Tripepi R, Tripepi G, Goligorsky MS, Zoccali C: Searching for biomarker patterns characterizing carotid atherosclerotic burden in patients with reduced renal function. Nephrol Dial Transplant 2007;22:3521–3526.
  13. Honda H, Qureshi AR, Heimburger O, Barany P, Wang K, Pecoits-Filho R, Stenvinkel P, Lindholm B: Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 2006;47:139–148.
  14. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, Collins R: Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007;370:1829–1839.
  15. Vaziri ND, Moradi H: Mechanisms of dyslipidemia of chronic renal failure. Hemodial Int 2006;10:1–7.
  16. Vaziri ND: Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 2006;290:F262–F272.
  17. Fliser D, Pacini G, Engelleiter R, Kautzky-Willer A, Prager R, Franek E, Ritz E: Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 1998;53:1343–1347.
  18. Sechi LA, Catena C, Zingaro L, Melis A, De Marchi S: Abnormalities of glucose metabolism in patients with early renal failure. Diabetes 2002;51:1226–1232.
  19. Charlesworth JA, Kriketos AD, Jones JE, Erlich JH, Campbell LV, Peake PW: Insulin resistance and postprandial triglyceride levels in primary renal disease. Metabolism 2005;54:821–828.
  20. Prinsen BH, de Sain-van der Velden MG, de Koning EJ, Koomans HA, Berger R, Rabelink TJ: Hypertriglyceridemia in patients with chronic renal failure: possible mechanisms. Kidney Int Suppl 2003;84:S121–S124.
  21. Vaziri ND, Liang K: Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure. Kidney Int 1996;50:1928–1935.
  22. Vaziri ND, Liang K, Parks JS: Down-regulation of hepatic lecithin:cholesterol acyltransferase gene expression in chronic renal failure. Kidney Int 2001;59:2192–2196.
  23. Mori Y, Hirano T, Nagashima M, Shiraishi Y, Fukui T, Adachi M: Decreased peroxisome proliferator-activated receptor alpha gene expression is associated with dyslipidemia in a rat model of chronic renal failure. Metabolism 2007;56:1714–1718.
  24. Lee DM, Knight-Gibson C, Samuelsson O, Attman PO, Wang CS, Alaupovic P: Lipoprotein particle abnormalities and the impaired lipolysis in renal insufficiency. Kidney Int 2002;61:209–218.
  25. Cheung AK, Parker CJ, Ren K, Iverius PH: Increased lipase inhibition in uremia: identification of pre-beta-HDL as a major inhibitor in normal and uremic plasma. Kidney Int 1996;49:1360–1371.
  26. Akmal M, Kasim SE, Soliman AR, Massry SG: Excess parathyroid hormone adversely affects lipid metabolism in chronic renal failure. Kidney Int 1990;37:854–858.
  27. Vaziri ND, Wang XQ, Liang K: Secondary hyperparathyroidism downregulates lipoprotein lipase expression in chronic renal failure. Am J Physiol 1997;273:F925–F930.
  28. Akmal M, Perkins S, Kasim SE, Oh HY, Smogorzewski M, Massry SG: Verapamil prevents chronic renal failure-induced abnormalities in lipid metabolism. Am J Kidney Dis 1993;22:158–163.
  29. Despres JP, Lemieux I, Dagenais GR, Cantin B, Lamarche B: HDL-cholesterol as a marker of coronary heart disease risk: the Quebec cardiovascular study. Atherosclerosis 2000;153:263–272.
  30. Kontush A, Chapman MJ: Antiatherogenic small, dense HDL – guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med 2006;3:144–153.
  31. Attman PO, Samuelsson O, Alaupovic P: Lipoprotein metabolism and renal failure. Am J Kidney Dis 1993;21:573–592.
  32. Vaziri ND, Deng G, Liang K: Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure. Nephrol Dial Transplant 1999;14:1462–1466.
  33. Guarnieri GF, Moracchiello M, Campanacci L, Ursini F, Ferri L, Valente M, Gregolin C: Lecithin-cholesterol acyltransferase (LCAT) activity in chronic uremia. Kidney Int Suppl 1978;8:S26–S30.

    External Resources

  34. Kimura H, Miyazaki R, Imura T, Masunaga S, Suzuki S, Gejyo F, Yoshida H: Hepatic lipase mutation may reduce vascular disease prevalence in hemodialysis patients with high CETP levels. Kidney Int 2003;64:1829–1837.
  35. Dirican M, Akca R, Sarandol E, Dilek K: Serum paraoxonase activity in uremic predialysis and hemodialysis patients. J Nephrol 2004;17:813–818.
  36. Liberopoulos EN, Papavasiliou E, Miltiadous GA, Cariolou M, Siamopoulos KC, Tselepis AD, Elisaf MS: Alterations of paraoxonase and platelet-activating factor acetylhydrolase activities in patients on peritoneal dialysis. Perit Dial Int 2004;24:580–589.
  37. Milionis HJ, Elisaf MS, Tselepis A, Bairaktari E, Karabina SA, Siamopoulos KC: Apolipoprotein(a) phenotypes and lipoprotein(a) concentrations in patients with renal failure. Am J Kidney Dis 1999;33:1100–1106.
  38. Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C: Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 1987;80:458–465.
  39. Kronenberg F, Trenkwalder E, Lingenhel A, Friedrich G, Lhotta K, Schober M, Moes N, Konig P, Utermann G, Dieplinger H: Renovascular arteriovenous differences in Lp[a] plasma concentrations suggest removal of Lp[a] from the renal circulation. J Lipid Res 1997;38:1755–1763.
  40. Kostner KM, Maurer G, Huber K, Stefenelli T, Dieplinger H, Steyrer E, Kostner GM: Urinary excretion of apo(a) fragments. Role in apo(a) catabolism. Arterioscler Thromb Vasc Biol 1996;16:905–911.
  41. Haffner SM, Gruber KK, Aldrete G Jr, Morales PA, Stern MP, Tuttle KR: Increased lipoprotein(a) concentrations in chronic renal failure. J Am Soc Nephrol 1992;3:1156–1162.
  42. Bairaktari E, Elisaf M, Tsolas O, Siamopoulos KC: Serum Lp(a) levels in patients with moderate renal failure. Nephron 1998;79:367–368.
  43. Trenkwalder E, Gruber A, Konig P, Dieplinger H, Kronenberg F: Increased plasma concentrations of LDL-unbound apo(a) in patients with end-stage renal disease. Kidney Int 1997;52:1685–1692.
  44. Kronenberg F, Kuen E, Ritz E, Junker R, Konig P, Kraatz G, Lhotta K, Mann JF, Muller GA, Neyer U, Riegel W, Reigler P, Schwenger V, Von Eckardstein A: Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol 2000;11:105–115.
  45. Kronenberg F, Neyer U, Lhotta K, Trenkwalder E, Auinger M, Pribasnig A, Meisl T, Konig P, Dieplinger H: The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. J Am Soc Nephrol 1999;10:1027–1036.
  46. Longenecker JC, Klag MJ, Marcovina SM, Powe NR, Fink NE, Giaculli F, Coresh J: Small apolipoprotein(a) size predicts mortality in end-stage renal disease: The CHOICE study. Circulation 2002;106:2812–2818.
  47. Rajman I, Harper L, McPake D, Kendall MJ, Wheeler DC: Low-density lipoprotein subfraction profiles in chronic renal failure. Nephrol Dial Transplant 1998;13:2281–2287.
  48. Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ: Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation. Am J Kidney Dis 2000;35:852–862.
  49. St Pierre AC, Cantin B, Dagenais GR, Mauriege P, Bernard PM, Despres JP, Lamarche B: Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 2005;25:553–559.
  50. Baxter JH, Goodman HC, Havel RJ: Serum lipid and lipoprotein alterations in nephrosis. J Clin Invest 1960;39:455–465.
  51. Vega GL, Toto RD, Grundy SM: Metabolism of low density lipoproteins in nephrotic dyslipidemia: comparison of hypercholesterolemia alone and combined hyperlipidemia. Kidney Int 1995;47:579–586.
  52. Mallick NP, Short CD: The nephrotic syndrome and ischaemic heart disease. Nephron 1981;27:54–57.
  53. Moorhead JF, Brunton C, Fernando RL, Burns A, Varghese Z: Do glomerular atherosclerosis and lipid-mediated tubulo-interstitial disease cause progressive renal failure in man? Blood Purif 1996;14:58–66.
  54. Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ: The atherogenic lipoprotein phenotype: small dense LDL and lipoprotein remnants in nephrotic range proteinuria. Atherosclerosis 2001;157:211–220.
  55. Wanner C, Rader D, Bartens W, Kramer J, Brewer HB, Schollmeyer P, Wieland H: Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome. Ann Intern Med 1993;119:263–269.
  56. McKenzie IF, Nestel PJ: Studies on the turnover of triglyceride and esterified cholesterol in subjects with the nephrotic syndrome. J Clin Invest 1968;47:1685–1695.
  57. Demant T, Mathes C, Gutlich K, Bedynek A, Steinhauer HB, Bosch T, Packard CJ, Warwick GL: A simultaneous study of the metabolism of apolipoprotein B and albumin in nephrotic patients. Kidney Int 1998;54:2064–2080.
  58. Marsh JB, Sparks CE: Hepatic secretion of lipoproteins in the rat and the effect of experimental nephrosis. J Clin Invest 1979;64:1229–1237.
  59. Goldberg AC, Eliaschewitz FG, Quintao EC: Origin of hypercholesterolemia in chronic experimental nephrotic syndrome. Kidney Int 1977;12:23–27.
  60. Marsh JB: Lipoprotein metabolism in experimental nephrosis. J Lipid Res 1984;25:1619–1623.
  61. Davis RA, Engelhorn SC, Weinstein DB, Steinberg D: Very low density lipoprotein secretion by cultured rat hepatocytes. Inhibition by albumin and other macromolecules. J Biol Chem 1980;255:2039–2045.
  62. Appel GB, Blum CB, Chien S, Kunis CL, Appel AS: The hyperlipidemia of the nephrotic syndrome. Relation to plasma albumin concentration, oncotic pressure, and viscosity. N Engl J Med 1985;312:1544–1548.
  63. Yedgar S, Weinstein DB, Patsch W, Schonfeld G, Casanada FE, Steinberg D: Viscosity of culture medium as a regulator of synthesis and secretion of very low density lipoproteins by cultured hepatocytes. J Biol Chem 1982;257:2188–2192.
  64. Yamauchi A, Fukuhara Y, Yamamoto S, Yano F, Takenaka M, Imai E, Noguchi T, Tanaka T, Kamada T, Ueda N: Oncotic pressure regulates gene transcriptions of albumin and apolipoprotein B in cultured rat hepatoma cells. Am J Physiol 1992;263:C397–C404.
  65. Warwick GL, Caslake MJ, Boulton-Jones JM, Dagen M, Packard CJ, Shepherd J: Low-density lipoprotein metabolism in the nephrotic syndrome. Metabolism 1990;39:187–192.
  66. Warwick GL, Packard CJ, Demant T, Bedford DK, Boulton-Jones JM, Shepherd J: Metabolism of apolipoprotein B-containing lipoproteins in subjects with nephrotic-range proteinuria. Kidney Int 1991;40:129–138.
  67. Maugeais C, Braschi S, Ouguerram K, Maugeais P, Mahot P, Jacotot B, Darmaun D, Magot T, Krempf M: Lipoprotein kinetics in patients with analbuminemia. Evidence for the role of serum albumin in controlling lipoprotein metabolism. Arterioscler Thromb Vasc Biol 1997;17:1369–1375.
  68. Liang K, Vaziri ND: Gene expression of lipoprotein lipase in experimental nephrosis. J Lab Clin Med 1997;130:387–394.
  69. Shearer GC, Stevenson FT, Atkinson DN, Jones H, Staprans I, Kaysen GA: Hypoalbuminemia and proteinuria contribute separately to reduced lipoprotein catabolism in the nephrotic syndrome. Kidney Int 2001;59:179–189.
  70. Vaziri ND: Molecular mechanisms of lipid disorders in nephrotic syndrome. Kidney Int 2003;63:1964–1976.
  71. Vaziri ND, Sato T, Liang K: Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosis. Kidney Int 2003;63:1756–1763.
  72. Vaziri ND, Liang KH: Down-regulation of hepatic LDL receptor expression in experimental nephrosis. Kidney Int 1996;50:887–893.
  73. Vaziri ND, Liang K: Up-regulation of acyl-coenzyme A:cholesterol acyltransferase (ACAT) in nephrotic syndrome. Kidney Int 2002;61:1769–1775.
  74. Vaziri ND, Liang KH: Hepatic HMG-CoA reductase gene expression during the course of puromycin-induced nephrosis. Kidney Int 1995;48:1979–1985.
  75. Pahl MV, Oveisi F, Khamiseh G, Vaziri ND: Intestinal absorption and biliary secretion of cholesterol in rats with nephrotic syndrome. Nephrol Dial Transplant 1998;13:1446–1451.
  76. De Sain-Van Der Velden MG, Reijngoud DJ, Kaysen GA, Gadellaa MM, Voorbij H, Stellaard F, Koomans HA, Rabelink TJ: Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome. J Am Soc Nephrol 1998;9:1474–1481.
  77. Vaziri ND, Liang K, Parks JS: Acquired lecithin-cholesterol acyltransferase deficiency in nephrotic syndrome. Am J Physiol Renal Physiol 2001;280:F823–F828.
  78. Moulin P, Appel GB, Ginsberg HN, Tall AR: Increased concentration of plasma cholesteryl ester transfer protein in nephrotic syndrome: role in dyslipidemia. J Lipid Res 1992;33:1817–1822.
  79. Liang K, Vaziri ND: Down-regulation of hepatic high-density lipoprotein receptor, SR-B1, in nephrotic syndrome. Kidney Int 1999;56:621–626.
  80. Stenvinkel P, Alvestrand A, Angelin B, Eriksson M: LDL-apheresis in patients with nephrotic syndrome: effects on serum albumin and urinary albumin excretion. Eur J Clin Invest 2000;30:866–870.
  81. Muso E, Mune M, Fujii Y, Imai E, Ueda N, Hatta K, Imada A, Miki S, Kuwahara T, Takamitsu Y, Takemura T, Tsubakihara Y: Low density lipoprotein apheresis therapy for steroid-resistant nephrotic syndrome. Kansai-FGS-Apheresis Treatment (K-FLAT) Study Group. Kidney Int Suppl 1999;71:S122–S125.
  82. Kasiske BL, Velosa JA, Halstenson CE, La Belle P, Langendorfer A, Keane WF: The effects of lovastatin in hyperlipidemic patients with the nephrotic syndrome. Am J Kidney Dis 1990;15:8–15.
  83. Vaziri ND, Liang KH: Acyl-coenzyme A:cholesterol acyltransferase inhibition ameliorates proteinuria, hyperlipidemia, lecithin-cholesterol acyltransferase, SRB-1, and low-density lipoprotein receptor deficiencies in nephrotic syndrome. Circulation 2004;110:419–425.
  84. Attman PO, Samuelsson OG, Moberly J, Johansson AC, Ljungman S, Weiss LG, Knight-Gibson C, Alaupovic P: Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis. Kidney Int 1999;55:1536–1542.
  85. Okubo K, Ikewaki K, Sakai S, Tada N, Kawaguchi Y, Mochizuki S: Abnormal HDL apolipoprotein A-I and A-II kinetics in hemodialysis patients: a stable isotope study. J Am Soc Nephrol 2004;15:1008–1015.
  86. Blankestijn PJ, Vos PF, Rabelink TJ, van Rijn HJ, Jansen H, Koomans HA: High-flux dialysis membranes improve lipid profile in chronic hemodialysis patients. J Am Soc Nephrol 1995;5:1703–1708.
  87. Docci D, Capponcini C, Mengozzi S, Baldrati L, Neri L, Feletti C: Effects of different dialysis membranes on lipid and lipoprotein serum profiles in hemodialysis patients. Nephron 1995;69:323–326.
  88. Wanner C, Bahner U, Mattern R, Lang D, Passlick-Deetjen J: Effect of dialysis flux and membrane material on dyslipidaemia and inflammation in haemodialysis patients. Nephrol Dial Transplant 2004;19:2570–2575.
  89. Jung K, Scheifler A, Schulze BD, Scholz M: Lower serum high-density lipoprotein-cholesterol concentration in patients undergoing maintenance hemodialysis with acetate than with bicarbonate. Am J Kidney Dis 1995;25:584–588.
  90. Mordasini R, Frey F, Flury W, Klose G, Greten H: Selective deficiency of hepatic triglyceride lipase in uremic patients. N Engl J Med 1977;297:1362–1366.
  91. Shoji T, Nishizawa Y, Nishitani H, Yamakawa M, Morii H: Impaired metabolism of high density lipoprotein in uremic patients. Kidney Int 1992;41:1653–1661.
  92. Huttunen JK, Pasternack A, Vanttinen T, Ehnholm C, Nikkila EA: Lipoprotein metabolism in patients with chronic uremia. Effect of hemodialysis on serum lipoproteins and postheparin plasma triglyceride lipases. Acta Med Scand 1978;204:211–218.
  93. Katopodis KP, Elisaf M, Balafa O, Nikolopoulos P, Bairaktari E, Katsaraki A, Siamopoulos KC: Influence of the type of membrane and heparin on serum lipid parameters during a dialysis session: a pilot study. Am J Nephrol 2004;24:469–473.
  94. Schrader J, Stibbe W, Armstrong VW, Kandt M, Muche R, Kostering H, Seidel D, Scheler F: Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration. Kidney Int 1988;33:890–896.
  95. Chertow GM, Burke SK, Raggi P: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245–252.
  96. Kronenberg F, Lingenhel A, Neyer U, Lhotta K, Konig P, Auinger M, Wiesholzer M, Andersson H, Dieplinger H: Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients. Kidney Int Suppl 2003;84:S113–S116.
  97. Wheeler DC: Abnormalities of lipoprotein metabolism in CAPD patients. Kidney Int Suppl 1996;56:S41–S46.
  98. Heimburger O, Stenvinkel P, Berglund L, Tranoeus A, Lindholm B: Increased plasma lipoprotein(a) in continuous ambulatory peritoneal dialysis is related to peritoneal transport of proteins and glucose. Nephron 1996;72:135–144.
  99. Wanner C, Bartens W, Walz G, Nauck M, Schollmeyer P: Protein loss and genetic polymorphism of apolipoprotein(a) modulate serum lipoprotein(a) in CAPD patients. Nephrol Dial Transplant 1995;10:75–81.
  100. Kagan A, Bar-Khayim Y, Schafer Z, Fainaru M: Heterogeneity in peritoneal transport during continuous ambulatory peritoneal dialysis and its impact on ultrafiltration, loss of macromolecules and plasma level of proteins, lipids and lipoproteins. Nephron 1993;63:32–42.
  101. Siamopoulos KC, Elisaf M: Is CAPD atherogenic? Perit Dial Int 1997;17:227–231.
  102. Johansson AC, Samuelsson O, Attman PO, Haraldsson B, Moberly J, Knight-Gibson C, Alaupovic P: Dyslipidemia in peritoneal dialysis – relation to dialytic variables. Perit Dial Int 2000;20:306–314.
  103. Bredie SJ, Bosch FH, Demacker PN, Stalenhoef AF, van Leusen R: Effects of peritoneal dialysis with an overnight icodextrin dwell on parameters of glucose and lipid metabolism. Perit Dial Int 2001;21:275–281.
  104. Babazono T, Nakamoto H, Kasai K, Kuriyama S, Sugimoto T, Nakayama M, Hamada C, Furuya R, Hasegawa H, Kasahara M, Moriishi M, Tomo T, Miyazaki M, Sato M, Yorioka N, Kawaguchi Y: Effects of icodextrin on glycemic and lipid profiles in diabetic patients undergoing peritoneal dialysis. Am J Nephrol 2007;27:409–415.
  105. Kagan A, Bar-Khayim Y, Schafer Z, Fainaru M: Kinetics of peritoneal protein loss during CAPD. II. Lipoprotein leakage and its impact on plasma lipid levels. Kidney Int 1990;37:980–990.
  106. Kandoussi A, Cachera C, Reade R, Pagniez D, Fruchart JC, Tacquet A: Apo AIV in plasma and dialysate fluid of CAPD patients: comparison with other apolipoproteins. Nephrol Dial Transplant 1992;7:1026–1029.
  107. Katopodis KP, Andrikos EK, Gouva CD, Bairaktari ET, Nikolopoulos PM, Takouli LK, Tzallas CS, Elisaf MS, Pappas MV, Siamopoulos KC: Sevelamer hydrochloride versus aluminum hydroxide: effect on serum phosphorus and lipids in CAPD patients. Perit Dial Int 2006;26:320–327.
  108. Cattran DC, Steiner G, Wilson DR, Fenton SA: Hyperlipidemia after renal transplantation: natural history and pathophysiology. Ann Intern Med 1979;91:554–559.
  109. Kimak E, Solski J, Baranowicz-Gaszczyk I, Ksiazek A: A long-term study of dyslipidemia and dyslipoproteinemia in stable post-renal transplant patients. Ren Fail 2006;28:483–486.
  110. Ichimaru N, Takahara S, Kokado Y, Wang JD, Hatori M, Kameoka H, Inoue T, Okuyama A: Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. Atherosclerosis 2001;158:417–423.
  111. Mehrsai A, Khajehmougehi A, Afshar K, Emami M, Pourmand G: Lipids and lipoproteins alteration after renal transplantation. Nephrol Dial Transplant 1997;12:233–234.
  112. Tsakiris D, Caslake MJ, Briggs JD, Packard CJ, Shepherd J: Low-density lipoprotein metabolism following renal transplantation. Transplantation 1985;39:458–460.
  113. Quaschning T, Mainka T, Nauck M, Rump LC, Wanner C, Kramer-Guth A: Immunosuppression enhances atherogenicity of lipid profile after transplantation. Kidney Int Suppl 1999;71:S235–S237.
  114. Hilbrands LB, Demacker PN, Hoitsma AJ, Stalenhoef AF, Koene RA: The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients. J Am Soc Nephrol 1995;5:2073–2081.
  115. Kerschdorfer L, Konig P, Neyer U, Bosmuller C, Lhotta K, Auinger M, Hohenegger M, Riegler P, Margreiter R, Utermann G, Dieplinger H, Kronenberg F: Lipoprotein(a) plasma concentrations after renal transplantation: a prospective evaluation after 4 years of follow-up. Atherosclerosis 1999;144:381–391.
  116. Lindholm A, Albrechtsen D, Frodin L, Tufveson G, Persson NH, Lundgren G: Ischemic heart disease – major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation 1995;60:451–457.
  117. Ghosh P, Evans DB, Tomlinson SA, Calne RY: Plasma lipids following renal transplantation. Transplantation 1973;15:521–523.
  118. Kuster GM, Drexel H, Bleisch JA, Rentsch K, Pei P, Binswanger U, Amann FW: Relation of cyclosporine blood levels to adverse effects on lipoproteins. Transplantation 1994;57:1479–1483.
  119. Deleuze S, Garrigue V, Delmas S, Chong G, Swarcz I, Cristol JP, Mourad G: New onset dyslipidemia after renal transplantation: is there a difference between tacrolimus and cyclosporine? Transplant Proc 2006;38:2311–2313.
  120. Artz MA, Boots JM, Ligtenberg G, Roodnat JI, Christiaans MH, Vos PF, Blom HJ, Sweep FC, Demacker PN, Hilbrands LB: Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus. J Am Soc Nephrol 2003;14:1880–1888.
  121. Castello IB: Hyperlipidemia: a risk factor for chronic allograft dysfunction. Kidney Int Suppl 2002;80:73–77.
  122. Borissova AM, Djambazova A, Todorov K, Dakovska L, Tankova T, Kirilov G: Effect of erythropoietin on the metabolic state and peripheral insulin sensitivity in diabetic patients on haemodialysis. Nephrol Dial Transplant 1993;8:93.
  123. Kokot F, Wiecek A, Grzeszczak W, Klepacka J, Klin M, Lao M: Influence of erythropoietin treatment on endocrine abnormalities in haemodialyzed patients. Contrib Nephrol 1989;76:257–270.
  124. Riedel E, Hampl H, Scigalla P, Nundel M, Kessel M: Correction of amino acid metabolism by recombinant human erythropoietin therapy in hemodialysis patients. Kidney Int Suppl 1989;27:S216–S221.
  125. Mat O, Stolear JC, Georges B: Blood lipid profile in hemodialysis patients treated with human erythropoietin. Nephron 1992;60:236–237.
  126. Prata MM, Madeira C, Vicente O, Miguel MJ: Lipid profile in haemodialysis patients treated with recombinant human erythropoietin. Nephrol Dial Transplant 1998;13:2345–2347.
  127. Viron B, Donsimoni R, Michel C, al Khayat R, Mignon F: Effect of recombinant human erythropoietin on nutritional status and plasma lipids in uremic patients. Nephron 1992;60:249.
  128. Pollock CA, Wyndham R, Collett PV, Elder G, Field MJ, Kalowski S, Lawrence JR, Waugh DA, George CR: Effects of erythropoietin therapy on the lipid profile in end-stage renal failure. Kidney Int 1994;45:897–902.
  129. Allegra V, Martimbianco L, Vasile A: Lipid and apolipoprotein patterns during erythropoietin therapy: roles of erythropoietin, route of administration, and diet. Nephrol Dial Transplant 1997;12:924–932.
  130. Teplan V, Schuck O, Knotek A, Hajny J, Horackova M, Kvapil M: Enhanced metabolic effect of erythropoietin and keto acids in CRF patients on low-protein diet: Czech multicenter study. Am J Kidney Dis 2003;41:S26–S30.
  131. Siamopoulos KC, Gouva C, Katopodis KP, Tzallas C, Nikolopoulos P, Papavasiliou EC, Tselepis AD: Long-term treatment with EPO increases serum levels of high-density lipoprotein in patients with CKD. Am J Kidney Dis 2006;48:242–249.
  132. Papavasiliou EC, Gouva C, Siamopoulos KC, Tselepis AD: PAF-acetylhydrolase activity in plasma of patients with chronic kidney disease. Effect of long-term therapy with erythropoietin. Nephrol Dial Transplant 2006;21:1270–1277.
  133. Braumann KM, Nonnast-Daniel B, Boning D, Bocker A, Frei U: Improved physical performance after treatment of renal anemia with recombinant human erythropoietin. Nephron 1991;58:129–134.
  134. Tuzcu A, Bahceci M, Yilmaz E, Bahceci S, Tuzcu S: The comparison of insulin sensitivity in non-diabetic hemodialysis patients treated with and without recombinant human erythropoietin. Horm Metab Res 2004;36:716–720.
  135. Goto T, Saika H, Takahashi T, Maeda A, Mune M, Yukawa S: Erythropoietin supplement increases plasma lipoprotein lipase and hepatic triglyceride lipase levels in hemodialysis patients. Kidney Int Suppl 1999;71:S213–S215.
  136. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC: Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 2004;66:753–760.
  137. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 2003;41:I–IV, S1–S91.
  138. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486–2497.
  139. Bairaktari ET, Seferiadis KI, Elisaf MS: Evaluation of methods for the measurement of low-density lipoprotein cholesterol. J Cardiovasc Pharmacol Ther 2005;10:45–54.
  140. Bairaktari ET, Tzallas C, Kalientzidou M, Tselepis AD, Siamopoulos KC, Seferiadis KI, Elisaf MS: Evaluation of alternative calculation methods for determining low-density lipoprotein cholesterol in hemodialysis patients. Clin Biochem 2004;37:937–940.
  141. Desmeules S, Arcand-Bosse JF, Bergeron J, Douville P, Agharazii M: Nonfasting non-high-density lipoprotein cholesterol is adequate for lipid management in hemodialysis patients. Am J Kidney Dis 2005;45:1067–1072.
  142. Belani SS, Goldberg AC, Coyne DW: Ability of non-high-density lipoprotein cholesterol and calculated intermediate-density lipoprotein to identify nontraditional lipoprotein subclass risk factors in dialysis patients. Am J Kidney Dis 2004;43:320–329.
  143. Cressman MD, Heyka RJ, Paganini EP, O’Neil J, Skibinski CI, Hoff HF: Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 1992;86:475–482.
  144. Shoji T, Nishizawa Y, Kawagishi T, Kawasaki K, Taniwaki H, Tabata T, Inoue T, Morii H: Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. J Am Soc Nephrol 1998;9:1277–1284.
  145. Nishizawa Y, Shoji T, Kakiya R, Tsujimoto Y, Tabata T, Ishimura E, Nakatani T, Miki T, Inaba M: Non-high-density lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with end-stage renal disease. Kidney Int Suppl 2003;S117–S120.

    External Resources

  146. Shoji T, Nishizawa Y: Plasma lipoprotein abnormalities in hemodialysis patients – clinical implications and therapeutic guidelines. Ther Apher Dial 2006;10:305–315.
  147. Koch M, Kutkuhn B, Trenkwalder E, Bach D, Grabensee B, Dieplinger H, Kronenberg F: Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients. J Am Soc Nephrol 1997;8:1889–1898.
  148. Degoulet P, Legrain M, Reach I, Aime F, Devries C, Rojas P, Jacobs C: Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study. Nephron 1982;31:103–110.
  149. Lowrie EG, Lew NL: Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990;15:458–482.
  150. Iseki K, Yamazato M, Tozawa M, Takishita S: Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 2002;61:1887–1893.
  151. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, Tracy RP, Powe NR, Klag MJ: Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004;291:451–459.
  152. Kilpatrick RD, McAllister CJ, Kovesdy CP, Derose SF, Kopple JD, Kalantar-Zadeh K: Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol 2007;18:293–303.
  153. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267–1278.
  154. Lemos PA, Serruys PW, de Feyter P, Mercado NF, Goedhart D, Saia F, Arampatzis CA, Soares PR, Ciccone M, Arquati M, Cortellaro M, Rutsch W, Legrand V: Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy). Am J Cardiol 2005;95:445–451.
  155. Tonelli M, Moye L, Sacks FM, Kiberd B, Curhan G: Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 2003;138:98–104.
  156. Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, Craven T, West M: Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 2004;110:1557–1563.
  157. Holdaas H, Wanner C, Abletshauser C, Gimpelewicz C, Isaacsohn J: The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trials. Int J Cardiol 2007;117:64–74.
  158. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:23–33.
  159. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149–1158.
  160. Holdaas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, Fauchald P, Gronhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambuhl P, Olsson AG, Hartmann A, Solbu DO, Pedersen TR: Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003;361:2024–2031.
  161. Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ, Stehman-Breen CO: HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 2002;61:297–304.
  162. Mason NA, Bailie GR, Satayathum S, Bragg-Gresham JL, Akiba T, Akizawa T, Combe C, Rayner HC, Saito A, Gillespie BW, Young EW: HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis 2005;45:119–126.
  163. Goldfarb-Rumyantzev AS, Habib AN, Baird BC, Barenbaum LL, Cheung AK: The association of lipid-modifying medications with mortality in patients on long-term peritoneal dialysis. Am J Kidney Dis 2007;50:791–802.
  164. Wanner C, Krane V, Marz W, Olschewski M, Asmus HG, Kramer W, Kuhn KW, Kutemeyer H, Mann JF, Ruf G, Ritz E: Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics. Kidney Blood Press Res 2004;27:259–266.
  165. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238–248.
  166. Holmberg B, Brannstrom M, Bucht B, Crougneau V, Dimeny E, Ekspong A, Granroth B, Grontoft KC, Hadimeri H, Ingman B, Isaksson B, Johansson G, Lindberger K, Lundberg L, Mikaelsson L, Olausson E, Persson B, Welin D, Wikdahl AM, Stegmayr BG: Safety and efficacy of atorvastatin in patients with severe renal dysfunction. Scand J Urol Nephrol 2005;39:503–510.
  167. Ritz E, Wanner C: Lipid changes and statins in chronic renal insufficiency. J Am Soc Nephrol 2006;17:S226–S230.
  168. Kwan BC, Kronenberg F, Beddhu S, Cheung AK: Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol 2007;18:1246–1261.
  169. Wan RK, Mark PB, Jardine AG: The cholesterol paradox is flawed; cholesterol must be lowered in dialysis patients. Semin Dial 2007;20:504–509.
  170. Baigent C, Landry M: Study of heart and renal protection (SHARP). Kidney Int Suppl 2003;84:S207–S210.
  171. Fellstrom B, Zannad F, Schmieder R, Holdaas H, Jardine A, Rose H, Wilpshaar W; AURORA Study Group: Effect of rosuvastatin on outcomes in chronic haemodialysis patients – design and rationale of the AURORA study. Curr Control Trials Cardiovasc Med 2005;6:9.
  172. Backes JM, Gibson CA, Ruisinger JF, Moriarty PM: Fibrates: what have we learned in the past 40 years? Pharmacotherapy 2007;27:412–424.
  173. Brown WV: Expert commentary: the safety of fibrates in lipid-lowering therapy. Am J Cardiol 2007;99:19C–21C.
  174. Davidson MH, Armani A, McKenney JM, Jacobson TA: Safety considerations with fibrate therapy. Am J Cardiol 2007;99:3C–18C.
  175. Tonelli M, Collins D, Robins S, Bloomfield H, Curhan GC: Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. Kidney Int 2004;66:1123–1130.
  176. Chan MK: Gemfibrozil improves abnormalities of lipid metabolism in patients on continuous ambulatory peritoneal dialysis: the role of postheparin lipases in the metabolism of high-density lipoprotein subfractions. Metabolism 1989;38:939–945.
  177. Davidson MH, Stein EA, Bays HE, Maki KC, Doyle RT, Shalwitz RA, Ballantyne CM, Ginsberg HN: Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther 2007;29:1354–1367.

 goto top of outline Author Contacts

Prof. Kostas C. Siamopoulos, MSc, MD, FRSH
Department of Internal Medicine, Medical School
University of Ioannina
GR–451 10 Ioannina (Greece)
Tel. +30 26510 97507, Fax +30 26510 97016, E-Mail ksiamop@cc.uoi.gr

 goto top of outline Article Information

Received: March 12, 2008
Accepted: May 6, 2008
Published online: July 9, 2008
Number of Print Pages : 16
Number of Figures : 2, Number of Tables : 1, Number of References : 177

 goto top of outline Publication Details

American Journal of Nephrology

Vol. 28, No. 6, Year 2008 (Cover Date: October 2008)

Journal Editor: Bakris G. (Chicago, Ill.)
ISSN: 0250–8095 (Print), eISSN: 1421–9670 (Online)

For additional information: http://www.karger.com/AJN

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.